Immunovia AB (publ) (STO:IMMNOV)
Sweden
· Delayed Price · Currency is SEK 0.2660
-0.0040 (-1.48%)
Apr 24, 2025, 5:29 PM CET
Immunovia AB Revenue
In the year 2024, Immunovia AB had annual revenue of 931.00K SEK, down -40.89%. Immunovia AB had revenue of 455.00K in the quarter ending December 31, 2024, with 191.67% growth.
Revenue
931.00K
Revenue Growth
-40.89%
P/S Ratio
75.96
Revenue / Employee
103.44K
Employees
9
Market Cap
70.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 931.00K | -644.00K | -40.89% |
| Dec 31, 2023 | 1.58M | 430.00K | 37.55% |
| Dec 31, 2022 | 1.15M | 301.00K | 35.66% |
| Dec 31, 2021 | 844.00K | 482.00K | 133.15% |
| Dec 31, 2020 | 362.00K | 6.00K | 1.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.03B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.97B |
| Vitrolife AB | 3.61B |
| Bonesupport Holding AB | 898.73M |
| Vimian Group AB | 4.29B |
Immunovia AB News
- 2 months ago - Immunovia AB (LTS:0G8X) Q4 2024 Earnings Call Highlights: Breakthroughs in Testing and ... - GuruFocus
- 2 months ago - Q4 2024 Immunovia AB (publ) Earnings Call Transcript - GuruFocus
- 2 months ago - Immunovia reports Q4 results - Seeking Alpha
- 2 months ago - Immunovia initiates search for a new CFO - Seeking Alpha
- 5 months ago - Q3 2024 Immunovia AB (publ) Earnings Call Transcript - GuruFocus